Sarfraz Zouina, Nasir Zeeshan, Javad Faheem, Khan Aden, Shah Bushra, Khalid Musfira, Sarfraz Azza, Sarfraz Muzna, Minhas Amna, Gondal Suchal A
Fatima Jinnah Medical University, Lahore, Pakistan.
Nishtar Medical University, Multan, Pakistan.
J Community Hosp Intern Med Perspect. 2024 Sep 9;14(5):1-6. doi: 10.55729/2000-9666.1391. eCollection 2024.
This meta-analysis assesses the recent Food and Drug Administration (FDA)-approved antifungal, rezafungin, for treating candidemia and invasive candidiasis-both are significant health concerns with limited treatment options. Two randomized controlled trials comparing rezafungin to caspofungin were meta-analyzed, revealing no significant differences in global cure rates and 30-day all-cause mortality. While rezafungin's unique attributes, like a novel mechanism and once-weekly dosing, may enhance patient adherence, concerns arise about its clinical relevance given the substantial investment. The study emphasizes the need for ongoing research, post-marketing surveillance, and real-world data to determine rezafungin's true value in managing these life-threatening fungal infections. Despite FDA approval, further investigation is warranted for a comprehensive understanding of rezafungin's efficacy and safety.
这项荟萃分析评估了美国食品药品监督管理局（FDA）近期批准的抗真菌药物瑞扎芬净，用于治疗念珠菌血症和侵袭性念珠菌病——这两种都是严重的健康问题，且治疗选择有限。对两项比较瑞扎芬净与卡泊芬净的随机对照试验进行了荟萃分析，结果显示总体治愈率和30天全因死亡率无显著差异。虽然瑞扎芬净的独特特性，如新颖的作用机制和每周一次给药，可能会提高患者的依从性，但鉴于大量投入，其临床相关性令人担忧。该研究强调需要持续开展研究、进行上市后监测以及获取真实世界数据，以确定瑞扎芬净在管理这些危及生命的真菌感染中的真正价值。尽管已获FDA批准，但仍有必要进行进一步调查，以全面了解瑞扎芬净的疗效和安全性。
